Company

Mithradote Bio, Inc.

Mithradote Bio is developing a sublingual antidote for drug-facilitated sexual assault.

About

Mithradote Bio is developing M-101, a sublingual pan-antidote intended to counter the effects of benzodiazepines, Z drugs and other GABA agonists. Founded in 2023 by CEO Sophia Lee, the company is based in San Diego, US. In October 2024, it raised USD 1 million in seed funding co-led by TAHO Pharmaceuticals Ltd. and Vickers Venture Partners.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in